(CPIX) Cumberland Pharmaceuticals Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(CPIX) Cumberland Pharmaceuticals Inc. Complete Analysis Pack
Download Your Competitive Advantage
This Cumberland Pharmaceuticals Inc. BCG Matrix helps you quickly see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and portfolio planning. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Vibativ 750 mg IV, ABSSSI
Vibativ 750 mg IV is approved for acute bacterial skin and skin structure infections and is used in the hospital for serious Gram-positive infections. ABSSSI drives a large care need, with U.S. cases often cited at about 1.5 million a year, and antimicrobial resistance keeps demand for IV options active through 2025. That supports stronger growth potential than older legacy brands in Cumberland Pharmaceuticals Inc.'s portfolio.
Vibativ 750 mg IV, HAP/VAP
Vibativ 750 mg IV is approved for hospital-acquired and ventilator-associated bacterial pneumonia, two high-acuity inpatient settings with sustained treatment demand. In Cumberland Pharmaceuticals Inc.'s portfolio, that keeps the brand in a specialty anti-infective lane with room for hospital use expansion. The ICU pneumonia market is high value and recurring, so Vibativ fits a star-style growth profile.
Cadolor IV ibuprofen, acute pain
Cadolor IV ibuprofen is an injectable NSAID for pain and fever used in hospital and perioperative care. Acute-care analgesia is a recurring demand pool, so the brand fits a Stars profile when access widens. Formulary wins and strong placement matter most, because each new hospital account can lift repeat use fast.
Cadolor IV ibuprofen, fever control
Cadolor IV ibuprofen is approved for fever control and stays relevant because fever care is routine in inpatient and emergency settings. Since it is already commercialized and used in acute care, it supports Cumberland Pharmaceuticals Inc.’s growth side of the BCG matrix rather than a pure niche play.
- Approved for fever management
- Used in inpatient and ER care
- Commercialized, still clinically relevant
- Growth-side BCG profile
RediTrex methotrexate injection, rheumatology
RediTrex methotrexate injection is a Star for Cumberland Pharmaceuticals Inc. because it serves rheumatoid arthritis, juvenile idiopathic arthritis, and severe psoriatic disease, all of which need long-term treatment.
Its injectable format can support adoption versus oral-only methotrexate, especially when convenience and tolerability matter. Chronic rheumatology use also supports repeat demand, so it has better growth visibility than one-time-use products.
- Injectable methotrexate
- Repeat demand from chronic care
- Useful in RA, JIA, psoriasis
Cumberland’s Star Brands Drive Growth in Hospital and Chronic Care
In Cumberland Pharmaceuticals Inc., Stars are Vibativ, Cadolor IV, and RediTrex, which sit in higher-growth hospital and chronic-care niches. Vibativ benefits from serious Gram-positive infection demand, while Cadolor IV and RediTrex support repeat use in acute pain and rheumatology. These brands have stronger growth visibility than legacy assets, but they still need access wins and formulary pull.
| Brand | Key driver | BCG role |
|---|---|---|
| Vibativ | Hospital anti-infective demand | Star |
| Cadolor IV | Acute-care use | Star |
| RediTrex | Chronic repeat demand | Star |
What is included in the product
Detailed Word Document
Cumberland Pharmaceuticals’ BCG Matrix maps its drugs by growth and share to guide invest, hold, or divest decisions.
Editable Excel File
Quick BCG Matrix view of Cumberland Pharmaceuticals Inc. to pinpoint pain points and prioritize actions.
Reference Sources
Supports confidence by documenting credible sources behind Cumberland Pharmaceuticals Inc. claims, making the analysis easier to verify and use in decisions.
Cash Cows
Acetadote IV, acetaminophen poisoning
Acetadote IV is Cumberland Pharmaceuticals Inc.'s intravenous N-acetylcysteine antidote for acetaminophen poisoning, used in emergency and hospital care. Launched in 2004, it serves a mature, well-established market with recurring demand. That stability makes Acetadote a steady cash generator in the BCG matrix.
Acetadote 20-hour infusion, hospital use
Acetadote 20-hour infusion is Cumberland Pharmaceuticals Inc.'s core hospital N-acetylcysteine protocol for acetaminophen overdose, a clear acute event that drives use without broad promotion. The brand is established in hospitals and runs on a standard 20-hour IV pathway, which supports efficient operations and steady cash generation. With demand tied to episodic poisoning cases, mature usage favors low reinvestment and high margin retention.
Kristalose lactulose oral solution, chronic constipation
Kristalose, Cumberland Pharmaceuticals Inc.'s lactulose oral solution, is an oral prescription laxative for chronic constipation and a steady gastroenterology niche product. The segment is mature, not fast-growing, but the brand's long use and established prescribing base support recurring demand. That profile fits classic cash-cow territory: modest growth, durable sales, and reliable cash generation.
Kristalose lactulose oral solution, acute constipation
Kristalose, Cumberland Pharmaceuticals Inc.'s lactulose oral solution, stays in a mature cash-cow lane because acute and short-term constipation care is familiar to prescribers and pharmacies. Lactulose has long clinical use, so demand is steady even if growth is slow.
That low-growth profile can still pay off: recurring fills matter more than new-user growth, and constipation treatment is a common, repeat-use category.
- Short-term constipation use
- Well-known therapy area
- Recurring demand supports cash flow
- Low-growth, mature profile
Mature GI and antidote base
Cumberland Pharmaceuticals Inc.’s mature GI and antidote brands sit in established hospital niches, so they need little launch spend and mostly protect existing share. That is classic cash-cow behavior: low growth, steady demand, and a focus on retention over expansion. In Cumberland Pharmaceuticals Inc.’s latest 2025 filing, these older branded products still anchor the portfolio and help fund newer launches.
- Established GI and hospital niches
- Low promotion and launch spend
- Share defense, not demand creation
- Steady cash support for growth brands
Cumberland’s Cash Cows: Acetadote and Kristalose
Cumberland Pharmaceuticals Inc.’s cash cows are its long-standing hospital and GI brands, led by Acetadote IV and Kristalose. Acetadote’s 20-hour infusion protocol and Kristalose’s repeat-use constipation base sit in mature, low-growth niches, so they keep cash flowing with limited launch spend. In Cumberland Pharmaceuticals Inc.’s 2025 filing, these older products still help fund newer launches.
| Product | Maturity | Cash role |
|---|---|---|
| Acetadote IV | 2004 launch | Steady hospital demand |
| Kristalose | Mature GI brand | Recurring fills |
Preview Before You Purchase
Cumberland Pharmaceuticals Inc. Reference Sources
You’re previewing the exact Cumberland Pharmaceuticals Inc. BCG Matrix report you’ll receive after purchase. The full document is identical to this preview, with no demo pages or hidden content. It’s a clean, ready-to-use file you can download right away and apply in your strategic analysis.
Dogs
Omeclamox-Pak H. pylori kit
Omeclamox-Pak H. pylori kit targets Helicobacter pylori infection, but the treatment field is crowded with generic and combo regimens. That keeps pricing power weak and growth limited. For Cumberland Pharmaceuticals Inc., this fits the Dog box in the BCG Matrix: low share, low growth, and intense competition.
Omeclamox-Pak duodenal ulcer disease
Omeclamox-Pak is also used for duodenal ulcer disease, but that sits in a mature gastroenterology market with many low-cost alternatives. The branded pack format leaves little room for major growth, so the franchise looks like a dog in Cumberland Pharmaceuticals Inc.'s BCG mix. In a market led by entrenched PPI-based regimens, its expansion path is limited.
Vaprisol conivaptan, euvolemic hyponatremia
Vaprisol (conivaptan) is an injectable therapy for euvolemic hyponatremia in hospitalized patients, and its use stays tightly limited to that narrow setting. Approved in 2005, it is an older specialty product in a small, hospital-driven niche, so growth is usually slow and capped. That profile fits the Dog quadrant in Cumberland Pharmaceuticals Inc.'s BCG Matrix.
Vaprisol conivaptan, hypervolemic hyponatremia
Vaprisol (conivaptan) is used for euvolemic and hypervolemic hyponatremia, but the niche inpatient use keeps demand tight. In Cumberland Pharmaceuticals Inc.'s BCG view, it fits "Dogs" because the addressable market is specialized, not broad, and growth is limited versus larger hospital therapies.
Hypervolemic hyponatremia is mainly seen in heart failure, cirrhosis, and some ICU cases, so volume stays small. That means low market share and modest revenue traction, even if the drug remains clinically relevant.
- Specialized hospital use
- Small patient pool
- Low share, low growth
- BCG: Dogs
Legacy low-volume pack brands
Legacy low-volume pack brands are Cumberland Pharmaceuticals Inc.’s classic dog assets: older branded packs and niche hospital therapies with small sales bases, modest margins, and limited growth. They still need manufacturing, compliance, and sales support, but they usually do not move group revenue much. In BCG terms, they are cash-light, low-upside products that can stay in the portfolio only if they cover their own cost.
- Small sales base
- Support costs stay high
- Upside is limited
Two Cumberland Dogs in Crowded, Low-Growth Niches
Omeclamox-Pak and Vaprisol are Cumberland Pharmaceuticals Inc. Dogs: both sit in small, crowded niches with weak pricing power and limited growth. Vaprisol, approved in 2005, serves a narrow inpatient hyponatremia use case, while Omeclamox-Pak faces generic-heavy H. pylori and ulcer therapy competition.
| Asset | Dog signal |
|---|---|
| Omeclamox-Pak | Crowded, low-growth GI market |
| Vaprisol | Narrow hospital niche, slow growth |
Question Marks
Ifetroban Phase II, aspirin-exacerbated respiratory disease
Ifetroban is still in Phase II clinical testing for aspirin-exacerbated respiratory disease (AERD), a niche inflammatory airway disorder that affects an estimated 0.3% to 0.9% of people with asthma. The market could be meaningful if efficacy data hold, but Cumberland Pharmaceuticals Inc. has zero share before approval and launch. That makes Ifetroban a clear question mark in the BCG Matrix: high potential, no current revenue base.
Ifetroban Phase II, systemic sclerosis
Ifetroban is in Phase II for systemic sclerosis, a rare autoimmune disease that affects about 300,000 people in the United States. Cumberland Pharmaceuticals Inc. still needs clinical proof, and Phase II means the program has not yet shown enough data for approval. That makes it a classic Question Mark: high unmet need, but more capital and trial risk ahead.
Ifetroban Phase II, Duchenne muscular dystrophy
Ifetroban’s Phase II Duchenne muscular dystrophy work sits in a high-need rare disease with about 1 in 3,500 to 5,000 male births affected. DMD draws heavy research interest because patients still lack a curative therapy, so a successful result could be valuable. But Cumberland Pharmaceuticals Inc. has no commercial sales from this program yet, so it remains a BCG question mark.
Ifetroban Phase II, portal hypertension and hepatorenal syndrome
Ifetroban is a Phase II pipeline bet for Cumberland Pharmaceuticals Inc., with prior studies in hepatorenal syndrome and portal hypertension. These are severe liver-disease markets, and the asset is still experimental, so it needs more R&D spend before any commercial value shows up.
That makes it a classic Question Mark: high risk, but if efficacy holds in a setting where hepatorenal syndrome can carry very high short-term mortality, the upside could be large.
- Phase II completed
- Advanced liver indications
- High capital need
- High upside, high risk
Phase II hospital cholesterol candidate
Cumberland Pharmaceuticals Inc.'s hospital cholesterol candidate is still in Phase II, so it has early clinical risk and no proven approval path yet. Because it targets an acute-care setting, adoption would depend on clear hospital-use data, payer support, and a strong label; until then, it fits the BCG "question mark" bucket.
- Phase II only; early-stage risk remains high.
- Acute-care use can support faster uptake.
- Approval and sales are not established yet.
- Needs strong data to move beyond question mark.
Cumberland’s High-Risk, High-Reward Phase II Pipeline
Cumberland Pharmaceuticals Inc.'s Question Marks are mostly Ifetroban and other Phase II programs: they have no current sales base, but they target rare, high-need markets. Ifetroban spans AERD (0.3% to 0.9% of people with asthma), systemic sclerosis (about 300,000 U.S. patients), and DMD (1 in 3,500 to 5,000 male births), so the upside can be real if Phase II data hold. Until approval, these assets stay high-risk, cash-intensive bets.
| Asset | Stage | Why Question Mark |
|---|---|---|
| Ifetroban | Phase II | No sales; high upside |
| Hospital cholesterol candidate | Phase II | Early data only; no approval |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.